SynthesisBMC public health2026
Prevalence and treatment and control rates of hypertension among Chinese adults from 2016 to 2022: a meta-analysis.
Synthesis in BMC public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundHypertension is a leading cause of cardiovascular and cerebrovascular disease-related morbidity and mortality. This study aimed to investigate the prevalence, treatment rate and control rate of hypertension among Chinese adults from 2019 to the present through a meta-analysis, providing evidence for the development of strategies and measures for hypertension prevention and control at the national level.
methodsWe systematically searched PubMed, Embase, The Cochrane Library, CNKI, Wanfang and VIP to identify cross-sectional studies published from 2019 onwards that reported the prevalence, treatment rate and control rate of hypertension among Chinese adults aged ≥ 18 years. Study quality was assessed using a measurement tool developed by the U.S. Agency for Healthcare Research and Quality (AHRQ). Statistical analyses were performed using Stata 18.0. Pooled prevalence, treatment, and control rates were calculated via random-effects models, with meta-regression analysis and subgroup analyses conducted to assess heterogeneity.
resultsTwenty-seven studies involving 465,805 participants were included. The pooled age-standardized rates (2016-2022) were as follows: hypertension prevalence, 33.1% (95% CI: 29.3%, 37.0%); treatment rate, 32.8% (95% CI: 28.9%, 36.7%); and control rate, 14.9% (95% CI: 11.1%, 18.7%). Geographically, prevalence was highest in Northeast China (47.3%) and lowest in the West (33.3%), while the control rate showed an inverse pattern (West: 19.6%; Northeast: 12.6%) (both p < 0.001). Compared with rural residents, urban residents had a higher treatment rate (49.2% vs. 38.1%, p = 0.008). All three rates increased with age, reaching 59.4%, 42.9%, and 16.8% for prevalence, treatment, and control rates, respectively, in adults aged ≥ 60 years. Men had a higher prevalence than women (39.5% vs. 33.7%, p = 0.038), whereas women had a higher treatment rate (47.4% vs. 41.1%, p = 0.011).
conclusionHypertension remains a major public health challenge in China. It is essential not only to improve hypertension prevention strategies but also to optimize hypertension control measures while accounting for regional variations and age-related differences.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.